started · updated
Regeneron's Otarmeni gene therapy begins commercial use in US
A new gene therapy, Otarmeni (formerly DB-OTO), has moved beyond clinical trials to commercial application in the United States. Developed by Regeneron Pharmaceuticals, the treatment is designed for infants and adults suffering from severe to profound sensorineural hearing loss caused by mutations in both copies of the OTOF gene. This mutation prevents the production of otoferlin, a protein essential for transmitting sound signals to the brain.
Unlike cochlear implants, which use electrical signals to stimulate the auditory nerve, this therapy involves a surgical intervention to introduce a functional copy of the gene directly into the cochlea. The goal is to restore the biological mechanism of hearing through a single administration.
Boston Children's Hospital was the first center in the U.S. to commercially administer the treatment following FDA approval in April. Other authorized centers include Children's Wisconsin and Cincinnati Hospital Medical Center. Early clinical results have shown significant progress, including cases where pediatric patients demonstrated improved responses to voices and music.
Entities
Boston Children's Hospital · FDA · Otarmeni · Regeneron Pharmaceuticals